je.st
news
Regeneron skids on shortfall in Eylea sales
2014-11-05 00:27:56| Biotech - Topix.net
Regeneron Pharmaceuticals Inc. tumbled by more than $21 a share in morning trade Tuesday after the drug maker surprised investors with disappointing sales of a key product and reported third-quarter earnings that fell below forecasts. stumbled from grace as analysts said some of the air appears to be seeping from expectations for the company's blockbuster eye drug, Eylea.
Tags: sales
shortfall
skids
regeneron
Category:Biotechnology and Pharmaceuticals